EDGAR Online

TRANZYME INC

Reported by

CAPITAL REGIONAL ET COOPERATIF DESJARDINS

FORM 3

(Initial Statement of Beneficial Ownership)

Filed 04/01/11 for the Period Ending 04/01/11

Address	4819 EMPEROR BOULEVARD, SUITE 400 DURHAM, NC 27703
Telephone	919 313-4760
CIK	0001274644
Symbol	TZYM
SIC Code	2834 - Pharmaceutical Preparations
Fiscal Year	12/31

Powered By EDGAR Online
http://www.edgar-online.com
© Copyright 2011, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Date of Event Requiring Statement (MM/DD/YYYY)	3. Issuer Name **and** Ticker or Trading Symbol
Capital regional et cooperatif Desjardins	**4/1/2011**	**TRANZYME INC [TZYM]**
(Last) (First) (Middle) **2 COMPLEXE DESJARDINS, #1717, P.O. BOX 760**	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director ___ **X** ___ 10% Owner _____ Officer (give title below) _____ Other (specify below)	
(Street) **MONTREAL, QUEBEC, CANADA H5B 1B8** (City) (State) (Zip)	5. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ **X** _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (*e.g.* , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Common Exchangeable Shares of Tranzyme Pharma Inc.	(1)	(1)	**Common Stock**	**14497**	(1)	**D** (3)	
Preferred Exchangeable Shares of Tranzyme Pharma Inc.	(2)	(2)	**Common Exchangeable Shares of Tranzyme Pharma Inc.** (1)	**1217804**	(2)	**D** (3)	
Common Exchangeable Shares of Tranzyme Pharma	(1)	(1)	**Common Stock**	**29721**	(1)	**I** (4)	**By Desjardins-Innovatech**

Table II - Derivative Securities Beneficially Owned (*e.g.* , puts, calls, warrants, options, convertible securities)							
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Inc.							**S.E.C.**

Explanation of Responses:

(1) These shares of Tranzyme Pharma Inc. will be exchanged for shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011, in a corporate reorganization. These shares are immediately exercisable and have no expiration date.

(2) These shares of Tranzyme Pharma Inc. will be converted into Common Exchangeable Shares of Tranzyme Pharma Inc. immediately prior to the closing of the Issuer's initial public offering, which is anticipated to occur on April 6, 2011, in a corporate reorganization. These shares are immediately exercisable and have no expiration date.

(3) These securities are owned of record by Capital regional et cooperatif Desjardins, and ultimate control over voting and investment determinations with respect to the shares held by Capital regional et cooperatif Desjardins are made by the board of directors of Capital regional et cooperatif Desjardins, which is comprised of the following directors: Marlene Deveaux, Michael Dorosz, Maurice Doyon, Francine Ferland, Josee Fortin, Pierre Gauvreau, Evangeliste Bourdages, Andre Lachapelle, Steve Lepage, Jean-Claude Loranger, Bruno Morin, Jacques Plante and Claudine Roy, each of whom disclaims beneficial ownership of such securities except to the extent of his or her pecuniary interest therein.

(4) These securities are owned of record by Desjardins-Innovatech S.E.C. Ultimate control over voting and investment determinations with respect to the shares held by Desjardins-Innovatech S.E.C. are made by the board of directors of Capital regional et cooperatif Desjardins, which is comprised of the following directors: Marlene Deveaux, Michael Dorosz, Maurice Doyon, Francine Ferland, Josee Fortin, Pierre Gauvreau, Evangeliste Bourdages, Andre Lachapelle, Steve Lepage, Jean-Claude Loranger, Bruno Morin, Jacques Plante and Claudine Roy, each of whom disclaims beneficial ownership of such securities except to the extent of his or her pecuniary interest therein.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Capital regional et cooperatif Desjardins 2 COMPLEXE DESJARDINS, #1717 P.O. BOX 760 MONTREAL, QUEBEC, CANADA H5B 1B8		**X**		
Desjardins-Innovatech S.E.C. 2 COMPLEXE DESJARDINS, #1717 P.O. BOX 760 MONTREAL, QUEBEC, CANADA H5B 1B8		**X**		

Signatures

/s/ Renaud Lebuis, Legal Advisor and /s/ Gerald St. Aubin, Vice-President for Capital regional et cooperatif Desjardins — **4/1/2011**

** Signature of Reporting Person — Date

/s/ Renaud Lebuis, Legal Advisor and /s/ Gerald St. Aubin, Vice-President for Desjardins - Innovatech S.E.C. — **4/1/2011**

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

***** If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.